US Pharm. 2010;35(5):Epub.
San Francisco, CA—A study examining the impact of statins on the progression of multiple sclerosis (MS) found a lower incidence of new brain lesions in patients with early-stage disease who received an 80-mg daily dose of atorvastatin over 12 months. The randomized, placebo-controlled study was conducted by researchers at the University of California–San Francisco. Although the study was small (N = 81) and its primary endpoint—to evaluate MS progression in patients following their first attack—was not met, 55.3% of the statin group did not develop new brain lesions, versus 27.6% of the placebo group.
To comment on this article, contact rdavidson@uspharmacist.com.
